Brooklyn ImmunoTherapeutics (NYSE:BTX) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

BTX opened at $6.29 on Friday. Brooklyn ImmunoTherapeutics has a 12-month low of $6.06 and a 12-month high of $8.31. The stock has a market capitalization of $370.02 million, a PE ratio of -2.77 and a beta of 4.61. The firm’s fifty day moving average price is $3.99 and its 200 day moving average price is $1.88.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.